RT Journal Article
T1 Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics.
A1 van Werkhoven, Cornelis H
A1 Ducher, Annie
A1 Berkell, Matilda
A1 Mysara, Mohamed
A1 Lammens, Christine
A1 Torre-Cisneros, Julian
A1 Rodriguez-Baño, Jesus
A1 Herghea, Delia
A1 Cornely, Oliver A
A1 Biehl, Lena M
A1 Bernard, Louis
A1 Dominguez-Luzon, M Angeles
A1 Maraki, Sofia
A1 Barraud, Olivier
A1 Nica, Maria
A1 Jazmati, Nathalie
A1 Sablier-Gallis, Frederique
A1 de Gunzburg, Jean
A1 Mentre, France
A1 Malhotra-Kumar, Surbhi
A1 Bonten, Marc J M
A1 Vehreschild, Maria J G T
AB Trial enrichment using gut microbiota derived biomarkers by high-risk individuals can improve the feasibility of randomized controlled trials for prevention of Clostridioides difficile infection (CDI). Here, we report in a prospective observational cohort study the incidence of CDI and assess potential clinical characteristics and biomarkers to predict CDI in 1,007 patients ≥ 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta-lactamase inhibitor, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolones or clindamycin from 34 European hospitals. The estimated 90-day cumulative incidences of a first CDI episode is 1.9% (95% CI 1.1-3.0). Carbapenem treatment (Hazard Ratio (95% CI): 5.3 (1.7-16.6)), toxigenic C. difficile rectal carriage (10.3 (3.2-33.1)), high intestinal abundance of Enterococcus spp. relative to Ruminococcus spp. (5.4 (2.1-18.7)), and low Shannon alpha diversity index as determined by 16 S rRNA gene profiling (9.7 (3.2-29.7)), but not normalized urinary 3-indoxyl sulfate levels, predicts an increased CDI risk.
PB Nature Publishing Group
YR 2021
FD 2021-03-03
LK http://hdl.handle.net/10668/17578
UL http://hdl.handle.net/10668/17578
LA en
NO van Werkhoven CH, Ducher A, Berkell M, Mysara M, Lammens C, Torre-Cisneros J, et al.  Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics. Nat Commun. 2021 Apr 14;12(1):2240
NO This research project was supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement No. 115523, the Combatting Bacterial Resistance in Europe (COMBACTE) consortium, resources of which are composed of financial contribution from the European Union Seventh Framework Program (FP7/2007–2013) and Da Volterra, as a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies in kind and cash contribution. We thank Prof. Amee Manges (University of British Columbia, Vancouver, Canada)for providing the validation dataset utilized in this study.
DS RISalud
RD Apr 7, 2025